The Woodchuck Model of HDV Infection
- 785 Downloads
The Eastern woodchuck, Marmota monax, has been a useful model system for the study of the natural history of hepadnavirus infection and for the development and preclinical testing of antiviral therapies. The model has also been used for hepatitis delta virus (HDV). In this chapter several new applications of the woodchuck model of HDV infection are presented and discussed. The development of a woodchuck HDV inoculum derived from a molecular clone has facilitated the analysis of viral genetic changes occurring during acute and chronic infection. This analysis has provided insights into one of the more important aspects of the natural history of HDV infection—whether a superinfection becomes chronic. These results could renew interest in further vaccine development. An effective therapy for chronic HDV infection remains an important clinical goal for this agent, particularly because of the severity of the disease and the inability of current hepadnaviral therapies to ameliorate it. The recent application of the woodchuck model of chronic HDV infection to therapeutic development has yielded promising results which indicate that targeting the hepadnavirus surface protein may be a successful therapeutic strategy for HDV.
KeywordsHepatitis Delta Virus HBsAg Level Woolly Monkey Woodchuck Hepatitis Virus Hepatitis Delta Virus Infection
Unable to display preview. Download preview PDF.
- Gerin JL, Casey JL, Purcell RH (2001) Hepatitis Delta Virus. In: Knipe DM, Howley PM, (eds) Field’s Virology. 4 ed. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 3037–3050Google Scholar
- Karayiannis P, Saldanha J, Jackson AM, Luther S, Goldin R, Monjardino J, Thomas HC (1993) Partial control of hepatitis delta virus superinfection by immunisation of woodchucks (Marmota monax) with hepatitis delta antigen expressed by a recombinant vaccinia or baculovirus. J Med Virol 41:210–214PubMedGoogle Scholar
- Korba BE, Cote PJ, Menne S, Toshkov IA, Baldwin BH, Wells FV, Tennant BC, Gerin JL (2004) Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antiviral Therapy 9:937–952PubMedGoogle Scholar
- Menne S, Roneker CA, Korba BE, Gerin JL, Tennant BC, Cote PJ (2002) Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-βL-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76:5305–5314PubMedCrossRefGoogle Scholar
- Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC and others (2001) Antiviral activity of L-FMAU (1-(2-fluoro-5-methyl-b_L-arabinofuranosyl) uracil) against WHV replication and gene expression in chronically infected woodchucks. Hepatology 33:254–266PubMedCrossRefGoogle Scholar
- Purcell RH, Satterfield WC, Bergmann KF, Smedile A, Ponzetto A, Gerin JL (1987) Experimental hepatitis delta virus infection in the chimpanzee. In: Rizzetto M, Gerin JL, Purcell RH, (eds) The hepatitis delta virus and its infection. Alan R. Liss, New York, pp 27–36Google Scholar
- Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Arico S, Calzia R, Picciotto A, Colombo M, Popper H (1983) Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 98:437–441PubMedGoogle Scholar
- Tennant BC, Gerin JL (1994) The woodchuck model of hepatitis B virus infection. In: Shafritz DA, (ed) The Liver: Biology and Pathology. 3rd ed. Raven Press, Ltd., New York, pp 1455–1466Google Scholar